Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Oral Surg Oral Med Oral Pathol Oral Radiol ; 117(5): 608-616.e1, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24603057

RESUMO

OBJECTIVE: Ameloblastic carcinoma often poses diagnostic challenges in its separation from benign ameloblastoma with atypical cytologic features or an unusual clinical course. This study aimed to determine whether SOX2 (sex determining region-Y-related high mobility group box 2), a protein expressed in the epithelial basal proliferative zone in dentigerous cysts, is a marker for ameloblastic carcinoma as well as for high-grade transformation in ameloblastic neoplasms. STUDY DESIGN: Immunoperoxidase stains were performed according to a standard protocol. Immunostains were interpreted independently by 3 pathologists, and scores were recorded based on the percentage of staining and intensity of staining in the cells of interest. RESULTS: The diffuse strong nuclear staining pattern has 86.4% specificity (19 of 22) to indicate the presence of high-grade features and has 76.9% sensitivity (10 of 13) in comparison with benign counterparts (P = .0021). Although previously shown as a marker for ameloblastic neoplasms, calretinin is weakly positive in a few cells in 50% (5 of 10) of ameloblastic carcinoma and 43% (3 of 7) of benign ameloblastic neoplasms, with little value in highlighting the high-grade change (P = .36). CONCLUSIONS: The diffuse nuclear staining pattern of SOX2 is suggestive of a high-grade process in ameloblastic neoplasms. Numerous aggregates of cells harboring dense nuclear stain should raise concern for a malignancy.


Assuntos
Ameloblastoma/metabolismo , Biomarcadores Tumorais/metabolismo , Neoplasias Maxilomandibulares/metabolismo , Fatores de Transcrição SOXB1/metabolismo , Ameloblastoma/patologia , Humanos , Técnicas Imunoenzimáticas , Neoplasias Maxilomandibulares/patologia , Microscopia de Fluorescência , Sensibilidade e Especificidade
2.
Indian J Dent Res ; 24(3): 384-6, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24025890

RESUMO

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (DLBCL/BL) is a new category of B-cell lymphoma according to the 4 th edition of the World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008). The following report presents a case of this rare, newly described entity on the palate of a 59 year-old male.


Assuntos
Linfoma de Burkitt/patologia , Linfoma de Células B/patologia , Linfoma Difuso de Grandes Células B/patologia , Neoplasias Bucais/patologia , Anticorpos Monoclonais Murinos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Biomarcadores Tumorais/análise , Biópsia , Linfoma de Burkitt/tratamento farmacológico , Ciclofosfamida/uso terapêutico , Doxorrubicina/uso terapêutico , Humanos , Linfoma de Células B/tratamento farmacológico , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Neoplasias Bucais/tratamento farmacológico , Tomografia por Emissão de Pósitrons , Prednisona/uso terapêutico , Rituximab , Tomografia Computadorizada por Raios X , Vincristina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA